A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

NCT02519348 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

433

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Tremelimumab
BIOLOGICAL: Durvalumab
BIOLOGICAL: Bevacizumab

Sponsor

MedImmune LLC